Concepedia

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Shukui Qin, Masashi Kudo, T Meyer, RS Finn, Yibing Bai, Y. Guo, T. Zhang, Takeshi Satoh, A. Hiraoka, Donatella Marino,

Annals of Oncology · 2022 · 66 citations · 1 references

DOIFull text

Open access

Concepts

References

1

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Shukui Qin, Masashi Kudo, T Meyer et al. · Annals of Oncology · 2022 · 66 citations · Full text

, , +13